Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif., Dec. 26, 2023 -- (Healthcare Sales & Marketing Network) -- Amgen ... Biopharmaceuticals, Oncology, FDA Amgen, LUMAKRAS, sotorasib, non-small cell lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news